Apogee Enterprises (APOG) has laid out a mixed set of FY 2026 numbers, with Q3 revenue at US$348.6 million and basic EPS of US$0.78 alongside trailing twelve month EPS of US$1.87. Over recent quarters, revenue has ranged between US$341.3 million and US$358.2 million, while basic EPS has moved from a loss of US$0.13 per share in Q1 FY 2026 to US$1.40 at one point in FY 2025. This is setting the stage for investors to focus on how margins are holding up after a year marked by compressed profitability and a large one off loss.
With the headline figures on the table, the next step is to set these results against the most common narratives around Apogee Enterprises to see which margin stories still hold up and which ones need a rethink.
NasdaqGS:APOG Earnings & Revenue History as at Apr 2026
Margins Under Pressure, One Off Loss Still Lingers
Over the last 12 months, net profit margin sat at 2.9% compared with 7.1% the year before, and reported earnings were hit by a one off loss of US$46.3 million that pulled trailing net income down to US$40.0 million.
What bullish investors highlight is a five year earnings growth rate of 25.4% a year and plans to lift margins toward higher long term targets. However, the sharp gap between the recent 2.9% margin and the prior 7.1% margin, along with that US$46.3 million loss, raises the question of how quickly any margin recovery can show up in reported numbers.
Bulls point to cost savings initiatives and acquisitions as future margin drivers. The latest trailing data, though, still reflects lower profitability and a compressed earnings base at US$40.0 million.
This mix of a strong multi year growth record and a much lower recent margin means anyone leaning on the bullish story needs to separate the one off impact from the underlying run rate shown in the last few quarters.
Some readers will want to see how the optimistic thesis ties these recent margin numbers into a longer term story for the business. 🐂 Apogee Enterprises Bull Case
Valuation Gap vs 20.6x P/E Multiple
The shares trade on a trailing P/E of 20.6x, which sits above the peer average of 18.8x but below the broader US Building industry at 22.1x, while the current share price of US$38.29 is about 44.2% below a DCF fair value estimate of roughly US$68.65.
Consensus narrative points out that analysts see the stock as roughly fairly priced around a US$39.50 target. However, the combination of a 20.6x multiple and a DCF fair value of US$68.65 shows a wide spread between different valuation methods that investors need to weigh carefully.
On one hand, the P/E being slightly richer than peers but lower than the wider industry suggests the market is neither giving the company a clear premium nor heavily discounting it based on trailing earnings.
On the other hand, the DCF estimate sitting well above the current US$38.29 price and the more modest US$39.50 analyst target underlines how sensitive any valuation case is to assumptions about margins rebounding from the recent 2.9% level.
Quarterly EPS Swing and Bear Concerns
Within FY 2026, basic EPS moved from a loss of US$0.13 in Q1 to US$1.10 in Q2, then eased to US$0.78 in Q3, while quarterly net income went from a US$2.7 million loss in Q1 to US$23.6 million in Q2 and US$16.5 million in Q3 on relatively steady revenue between US$346.6 million and US$358.2 million.
Bears argue that heavy reliance on non residential construction and exposure to cost swings could keep this kind of earnings volatility in play. Yet the fact that revenue has stayed within a tight US$341.3 million to US$358.2 million band over the recent quarters suggests the main pressure is on margins rather than top line demand.
Concerns about input costs, tariffs and commercial project mix are backed up by the drop from a 7.1% margin to 2.9%, even though quarterly sales have held around US$1.4b on a trailing basis.
At the same time, the move from a Q1 loss to positive EPS in Q2 and Q3 shows that cost and mix actions can shift the bottom line quickly. This is a key counterpoint for anyone leaning fully into the bearish view.
For readers focused on the more cautious angle, it can help to line these swings up against a detailed breakdown of the risks that skeptics point to. 🐻 Apogee Enterprises Bear Case
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Apogee Enterprises on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Seen enough mixed signals to feel torn on Apogee Enterprises? Take a closer look at the full picture, weigh the opposing arguments, and ground your decision in the underlying data with 2 key rewards and 3 important warning signs.
Explore Alternatives
Apogee Enterprises is wrestling with compressed margins, a lingering one off loss and earnings volatility, even as revenue holds within a relatively tight range.
If those margin swings and profit hits feel uncomfortable, it could be worth balancing your watchlist with companies highlighted in the 72 resilient stocks with low risk scores that aim to keep earnings steadier.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.